A Phase 2, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of GS-5745 Combined With Nivolumab Versus Nivolumab Alone in Subjects With Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma
Latest Information Update: 31 Aug 2021
At a glance
- Drugs Andecaliximab (Primary) ; Nivolumab
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Sponsors Gilead Sciences
- 28 Aug 2019 Status changed from active, no longer recruiting to completed.
- 22 Mar 2019 This trial has been completed in Spain.
- 19 Jan 2019 Results (n=144) presented at the 2019 Gastrointestinal Cancers Symposium.